Summit Therapeutics PLC Asset Resilience Ratio
Summit Therapeutics PLC asset resilience ratio. Summit Therapeutics PLC (SMMT) has an Asset Resilience Ratio of 36.07% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Summit Therapeutics PLC defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Summit Therapeutics PLC (2004–2025)
Asset resilience ratio of Summit Therapeutics PLC from 2004 to 2025. This chart shows how Summit Therapeutics PLC's Asset Resilience Ratio has changed over time. Read Summit Therapeutics PLC balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Summit Therapeutics PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Summit Therapeutics PLC balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $271.31 Million | 36.07% |
| Total Liquid Assets | $271.31 Million | 36.07% |
Asset Resilience Insights
- Very High Liquidity: Summit Therapeutics PLC maintains exceptional liquid asset reserves at 36.07% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Summit Therapeutics PLC Industry Peers by Asset Resilience Ratio
Compare Summit Therapeutics PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Summit Therapeutics PLC Asset Resilience Ratio by Year (2004–2025)
Summit Therapeutics PLC asset resilience ratio by year from 2004 to 2025. The table below shows the annual Asset Resilience Ratio data for Summit Therapeutics PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 64.99% | $362.31 Million | $557.50 Million | -5.61pp |
| 2024-12-31 | 70.60% | $245.71 Million | $348.05 Million | +14.02pp |
| 2023-12-31 | 56.57% | $90.86 Million | $160.60 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $541.43 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $79.53 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $76.38 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $46.98 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $35.71 Million | -- |
| 2005-12-31 | 80.01% | $20.70 Million | $25.87 Million | +3.01pp |
| 2004-12-31 | 77.00% | $20.70 Million | $26.88 Million | -- |
About Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cance… Read more